Flu Vaccine Guide — Everything You Need to Know

The influenza vaccine is the single most effective tool we have for preventing flu and its complications. Each year, the vaccine prevents millions of illnesses, hundreds of thousands of hospitalizations, and thousands of deaths. This guide covers the types of flu vaccines available, how they're made, how effective they actually are, who should get vaccinated, and the evidence behind common concerns.

How the Flu Vaccine Works

The flu vaccine works by presenting your immune system with inactivated or weakened flu virus antigens (proteins from the virus) or with instructions (mRNA) to make those antigens. Your immune system then produces antibodies against these antigens. If you're later exposed to the actual flu virus, those pre-existing antibodies recognize and neutralize it before it can establish a serious infection.

It takes approximately two weeks after vaccination for protective antibodies to develop. This is why getting vaccinated early in the flu season — before widespread circulation begins — is important. You are not protected the day after you receive the shot.

Types of Flu Vaccines Available

Inactivated Influenza Vaccines (IIV) — The Standard Shot

These are the most commonly administered flu vaccines. They contain influenza viruses that have been chemically inactivated (killed) so they cannot cause infection. Subtypes include:

• Standard-dose quadrivalent IIV: Contains four flu virus strains — two influenza A strains (H1N1 and H3N2) and two influenza B strains (Victoria and Yamagata lineages). "Quadrivalent" means 4-strain coverage. This is the most widely used formulation. Approved for everyone 6 months and older.
• High-dose IIV (Fluzone High-Dose): Contains four times the antigen of standard-dose vaccines. Specifically designed for adults 65 and older, whose immune systems generate a less robust response to standard vaccines. A 2014 study in the New England Journal of Medicine found high-dose vaccine was 24% more effective at preventing laboratory-confirmed flu in older adults compared to standard-dose vaccine.
• Adjuvanted IIV (Fluad): Contains the adjuvant MF59 (squalene oil-in-water emulsion), which boosts the immune response. Also designed for adults 65 and older. Adjuvanted and high-dose vaccines have comparable effectiveness in this population.
• Cell-culture-based IIV (Flucelvax): Grown in mammalian cell culture rather than chicken eggs. This avoids egg-adaptive mutations that can reduce vaccine effectiveness, particularly for influenza A(H3N2) strains. May offer a slight effectiveness advantage in seasons when egg-adapted changes are significant.

Recombinant Influenza Vaccine (RIV — Flublok)

Unlike IIVs, recombinant vaccines are produced without using flu virus or chicken eggs at any stage. The gene for the hemagglutinin (HA) protein — the main surface protein of the flu virus — is inserted into a baculovirus that infects insect cells, which then produce large quantities of purified HA protein. Key features:

• Contains three times the HA antigen of standard-dose IIVs (45 µg per strain vs. 15 µg).
• No egg proteins — suitable for people with severe egg allergy.
• Avoids egg-adaptive mutations entirely.
• Approved for adults 18 and older.
• In a 2017 study in the New England Journal of Medicine, Flublok was approximately 30% more effective than standard-dose IIV in adults 50 and older.

Live Attenuated Influenza Vaccine (LAIV — FluMist® Nasal Spray)

LAIV contains live flu viruses that have been weakened (attenuated) so they cannot cause illness in healthy people. The viruses replicate in the cooler temperatures of the nasal passages but cannot survive at the warmer core body temperature. This limited replication stimulates a strong immune response, including mucosal IgA antibodies at the site where the flu virus enters the body.

Key facts:

• Administered as a nasal spray — no needle.
• Approved for healthy, non-pregnant people aged 2 through 49 years.
• Not recommended for: pregnant women, immunocompromised individuals, children under 2 or adults 50+, people with asthma or recent wheezing, people taking aspirin-containing therapy (Reye's syndrome risk in children), people with cochlear implants or CSF leaks.
• Effectiveness: After being found ineffective against H1N1 during the 2013–14 and 2015–16 seasons, the manufacturer reformulated the H1N1 component. Since the 2018–19 season (when the ACIP re-recommended LAIV), data has been limited but generally comparable to IIVs when the match is good.

How Effective Is the Flu Vaccine?

Flu vaccine effectiveness (VE) varies from season to season, typically ranging from 20% to 60% in preventing medically attended flu illness. The variation depends primarily on two factors:

1. Vaccine match: How well the vaccine strains match the circulating strains. The WHO selects vaccine strains in February (Northern Hemisphere) and September (Southern Hemisphere) based on global surveillance data — a prediction made 6–9 months before peak flu season. Most seasons, the match is good. Some seasons, circulating viruses drift enough that protection is reduced. H3N2 strains are particularly prone to egg-adaptive mutations during manufacturing, which can reduce VE.
2. Host factors: The recipient's age, immune status, and prior flu exposure history all affect vaccine response. Older adults consistently have lower VE, which is why enhanced vaccines (high-dose, adjuvanted, recombinant) are recommended for this group.

Recent VE data (selected seasons):

• 2022–2023: ~54% against medically attended flu A in children, ~30% in adults. Against flu B: ~70%.
• 2023–2024: ~42–52% against medically attended flu overall in the US. Higher against H1N1 (~60%), lower against H3N2 (~30%).
• 2024–2025: Interim estimates showed ~34–50% effectiveness depending on strain and age group.

Effectiveness against severe outcomes is higher than against illness alone. Even in seasons where VE against any flu illness is modest (20–30%), VE against hospitalization is consistently stronger (40–60%), and VE against death is stronger still. A 2021 meta-analysis in Vaccine found flu vaccination reduced ICU admission risk by 26–59% in adults and reduced the risk of death by 31–52%. In children, flu vaccination reduced the risk of flu-related death by 65% among healthy children and 51% among those with high-risk medical conditions (2017 study in Pediatrics).

A useful analogy: the flu vaccine is like a seatbelt. It doesn't prevent every injury in every crash, but in a serious crash, the difference between wearing one and not wearing one is often the difference between walking away and being carried away.

Who Should Get Vaccinated

The CDC recommends annual flu vaccination for everyone 6 months and older, with rare exceptions (see contraindications below). The recommendation is universal because:

• Influenza can cause severe illness in anyone, including previously healthy people.
• Even if you personally experience only mild flu, you can transmit the virus to people at high risk — infants too young to be vaccinated, immunocompromised individuals, and older adults.
• Widespread vaccination creates community immunity (herd protection) that protects those who cannot be vaccinated or respond less well to vaccination.

Highest Priority Groups

While everyone should get vaccinated, these groups are at highest risk for severe flu and complications:

• Children aged 6 months through 4 years
• Adults aged 50 and older (especially 65+)
• Pregnant women (any trimester) and women up to 2 weeks postpartum
• Residents of nursing homes and long-term care facilities
• People with chronic medical conditions: asthma, COPD, heart disease, diabetes, kidney disease, liver disease, immunocompromised states (including HIV), neurological conditions, obesity (BMI ≥ 40)
• Healthcare workers and caregivers of high-risk individuals
• American Indian and Alaska Native people (disproportionately affected by severe flu)

Pregnant Women: Special Considerations

Pregnancy increases the risk of severe influenza, hospitalization, and death by approximately 2–3 fold. The flu vaccine is recommended during any trimester of pregnancy and is one of the most studied interventions in pregnancy — decades of data demonstrate its safety. Additionally, maternal vaccination passes protective antibodies to the baby through the placenta, providing protection during the first months of life when the infant is too young to be vaccinated. A 2016 randomized controlled trial in Lancet Infectious Diseases found that maternal flu vaccination reduced laboratory-confirmed flu in infants under 6 months by approximately 50%.

Who Should NOT Get Vaccinated — Contraindications and Precautions

Absolute Contraindications

• Severe allergic reaction (anaphylaxis) to a previous dose of any flu vaccine — regardless of vaccine type.
• Severe allergic reaction to any component of the vaccine (excluding egg — see below).
• Infants under 6 months of age — the vaccine is not approved for this age group. Protection is provided indirectly through maternal vaccination during pregnancy.

Precautions (Vaccination Decision Should Be Individualized)

• History of Guillain-Barré Syndrome (GBS) within 6 weeks of a previous flu vaccine: The absolute risk of GBS after flu vaccination is approximately 1–2 cases per million doses — far lower than the risk of GBS after influenza infection itself (approximately 17 cases per million flu cases). For most people with a history of GBS, the benefits of vaccination still outweigh the risks, but the decision should be made with a healthcare provider.
• Moderate or severe acute illness with or without fever: Vaccination should be deferred until the acute illness resolves. Mild illness (cold, low-grade fever) is not a contraindication.

LAIV (Nasal Spray) Specific Contraindications

• Pregnancy
• Immunocompromised states (including HIV with low CD4 count)
• Children aged 2–4 years with asthma or wheezing in the past 12 months
• People taking aspirin or salicylate-containing medications (Reye's syndrome risk in children)
• Cochlear implant or active CSF leak
• Close contacts of severely immunocompromised persons requiring a protected environment
• Children under 2 years and adults over 49 years

Egg Allergy and the Flu Vaccine

Most flu vaccines are produced using chicken eggs, and trace amounts of egg protein (ovalbumin) may remain in the final product. The concern about egg allergy and flu vaccination has been extensively studied, and current evidence is clear:

• The CDC and ACIP state that people with egg allergy of any severity may receive any flu vaccine (egg-based or non-egg-based) appropriate for their age and health status.
• Severe allergic reactions to egg-based flu vaccines in people with egg allergy are extremely rare — approximately 1.3 per million doses, which is no higher than the rate in the general population.
• No special observation period or allergy testing is required for people with egg allergy receiving any flu vaccine.
• The amount of residual egg protein in flu vaccines today is very low (typically <1 µg per dose, compared to the approximately 30 µg needed to trigger a reaction in even highly egg-allergic individuals).
• For those who prefer to avoid egg-based vaccines entirely, cell-culture-based (Flucelvax) and recombinant (Flublok) vaccines are egg-free alternatives.

Timing: When Should You Get Vaccinated?

For the Northern Hemisphere, the optimal vaccination window is September through October. Key timing considerations:

• Flu activity typically peaks between December and February but can extend into May. The season is unpredictable year to year.
• The vaccine provides protection for approximately 6–8 months. Immunity does wane over time, which is why annual vaccination is needed.
• Getting vaccinated too early (July/August) raises the concern that protection may wane before the end of the season, particularly in older adults. The CDC recommends against vaccination before September for most people, except for children who need two doses (see below) and pregnant women in their third trimester during July/August.
• Getting vaccinated later is still worthwhile. As long as flu viruses are circulating, vaccination provides benefit. January, February, and even March vaccination can still protect against late-season activity.
• Children aged 6 months through 8 years who are receiving the flu vaccine for the first time (or who previously received only one dose) need two doses at least 4 weeks apart. These children should receive their first dose as soon as vaccine becomes available (even July/August) so the second dose can be administered before the season peaks.

Common Side Effects

• Injection site reactions: Soreness, redness, and swelling at the injection site — occurs in 15–30% of recipients. Typically resolves within 24–48 hours. This is a local immune response and is normal.
• Systemic symptoms: Low-grade fever, mild headache, muscle aches, and fatigue — occur in 5–10% of recipients, more commonly in people who have not been exposed to the vaccine strains before (e.g., young children receiving their first dose). These symptoms last 1–2 days and reflect the immune system generating its response. They are significantly milder than actual influenza and are not contagious.
• Serious adverse events: Extremely rare. Anaphylaxis occurs at a rate of approximately 1–2 per million doses. Guillain-Barré Syndrome occurs at approximately 1–2 cases per million doses (the association is not fully established, and the risk from influenza infection itself is far higher).

What About mRNA Flu Vaccines?

Following the success of mRNA COVID-19 vaccines, several manufacturers (Moderna, Pfizer/BioNTech, Sanofi/Translate Bio) are developing mRNA-based flu vaccines. Potential advantages include faster manufacturing (no egg adaptation needed), the ability to update strains more quickly as circulating viruses change, and the potential for combination COVID-flu vaccines. As of 2026, mRNA flu vaccines are in late-stage clinical trials but are not yet licensed for general use. The current standard of care remains egg-based, cell-culture, and recombinant vaccines.

Key Takeaways

• The flu vaccine is recommended for everyone 6 months and older, with very few exceptions.
• Effectiveness varies by season (typically 20–60% against illness), but protection against hospitalization and death is consistently stronger.
• Adults 65+ should receive enhanced vaccines: high-dose (Fluzone High-Dose), adjuvanted (Fluad), or recombinant (Flublok).
• Pregnant women should be vaccinated in any trimester — it protects both mother and baby.
• Egg allergy of any severity is no longer a contraindication to any flu vaccine. Egg-free options are also available.
• Optimal vaccination timing: September–October for most people. Earlier for children needing two doses.
• Side effects are generally mild and last 1–2 days. The vaccine cannot cause influenza.
• Even a "less effective" vaccine in a bad-match year prevents severe illness, hospitalization, and death.